Our top pick for
Cancer Genetics, Inc is a biotechnology business based in the US. Cancer Genetics shares (CGIX) are listed on the NASDAQ and all prices are listed in US Dollars. Cancer Genetics employs 110 staff and has a trailing 12-month revenue of around USD$6.3 million.
|52-week range||USD$1.92 - USD$7.7|
|50-day moving average||USD$4.4912|
|200-day moving average||USD$3.7115|
|Wall St. target price||USD$3|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.515|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$6.3 million|
|Gross profit TTM||USD$3.6 million|
|Return on assets TTM||-14.9%|
|Return on equity TTM||-68.71%|
|Market capitalisation||USD$52.4 million|
TTM: trailing 12 months
There are currently 220,441 Cancer Genetics shares held short by investors – that's known as Cancer Genetics's "short interest". This figure is 208.6% up from 71,437 last month.
There are a few different ways that this level of interest in shorting Cancer Genetics shares can be evaluated.
Cancer Genetics's "short interest ratio" (SIR) is the quantity of Cancer Genetics shares currently shorted divided by the average quantity of Cancer Genetics shares traded daily (recently around 1.2 million). Cancer Genetics's SIR currently stands at 0.18. In other words for every 100,000 Cancer Genetics shares traded daily on the market, roughly 180 shares are currently held short.
However Cancer Genetics's short interest can also be evaluated against the total number of Cancer Genetics shares, or, against the total number of tradable Cancer Genetics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cancer Genetics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Cancer Genetics shares in existence, roughly 50 shares are currently held short) or 0.0552% of the tradable shares (for every 100,000 tradable Cancer Genetics shares, roughly 55 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cancer Genetics.
Find out more about how you can short Cancer Genetics stock.
We're not expecting Cancer Genetics to pay a dividend over the next 12 months.
Cancer Genetics's shares were split on a 1:30 basis on 25 October 2019. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cancer Genetics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Cancer Genetics shares which in turn could have impacted Cancer Genetics's share price.
Over the last 12 months, Cancer Genetics's shares have ranged in value from as little as $1.92 up to $7.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cancer Genetics's is 2.6505. This would suggest that Cancer Genetics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.